Fmr LLC Decreases Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

FMR LLC decreased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 97.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 67,165 shares of the company's stock after selling 2,475,841 shares during the quarter. FMR LLC owned approximately 0.15% of Pacira BioSciences worth $1,011,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP boosted its position in Pacira BioSciences by 12.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company's stock valued at $52,300,000 after acquiring an additional 198,936 shares during the last quarter. Pacer Advisors Inc. boosted its position in Pacira BioSciences by 129.4% during the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company's stock valued at $74,681,000 after acquiring an additional 2,799,434 shares during the last quarter. Legato Capital Management LLC boosted its position in Pacira BioSciences by 74.0% during the second quarter. Legato Capital Management LLC now owns 52,913 shares of the company's stock valued at $1,514,000 after acquiring an additional 22,497 shares during the last quarter. WINTON GROUP Ltd bought a new stake in Pacira BioSciences during the second quarter valued at $2,726,000. Finally, Banco Santander S.A. bought a new stake in Pacira BioSciences during the second quarter valued at $3,959,000. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Down 0.2 %

Shares of PCRX traded down $0.04 on Tuesday, reaching $19.83. The company's stock had a trading volume of 690,329 shares, compared to its average volume of 850,727. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $35.95. The stock has a market capitalization of $915.61 million, a PE ratio of -9.79 and a beta of 0.80. The firm has a fifty day moving average of $17.35 and a 200-day moving average of $18.89.

Analyst Ratings Changes

A number of brokerages have commented on PCRX. Barclays cut their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a "buy" rating and set a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Royal Bank of Canada increased their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research report on Thursday, November 7th. Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a research report on Friday, November 8th. Finally, Jefferies Financial Group increased their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $23.50.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.